言語を選択

Coagulation factor XI

Coagulation factor XI 詳細

英語名	Coagulation factor XI	市販薬剤の数	2
治験薬の数	30	ターゲットの別称	EC 3.4.21，EC:3.4.21.27，FXI，F11，PTA，Coagulation Factor XI，Plasma Thromboplastin Antecedent，EC 3.4.21.27，Factor XI，Coagualtion Factor XI
研究＆開発段階	Approved

英語名	Coagulation factor XI
ターゲットの別称	EC 3.4.21，EC:3.4.21.27，FXI，F11，PTA，Coagulation Factor XI，Plasma Thromboplastin Antecedent，EC 3.4.21.27，Factor XI，Coagualtion Factor XI
市販薬剤の数	2
治験薬の数	30
研究＆開発段階	Approved

Coagulation factor XI 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (1)Rhesus macaque (1)
タグ
His Tag (2)
マーカー
Unconjugated (2)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
FXI-H52H5	Human	HEK293	Human Coagulation factor XI / FXI Protein, His Tag (active enzyme)
FXI-C52H3	Rhesus macaque	HEK293	Rhesus macaque Coagulation factor XI Protein, His Tag (Pro-form)

総数量2

Coagulation factor XIバックグランド

This protein is present in plasma as a zymogen, which is a unique plasma coagulation enzyme because it exists as a homodimer consisting of two identical polypeptide chains linked by disulfide bonds. During activation of the plasma factor XI, an internal peptide bond is cleaved by factor XIIa (or XII) in each of the two chains, resulting in activated factor XIa, a serine protease composed of two heavy and two light chains held together by disulfide bonds. This activated plasma factor XI triggers the middle phase of the intrisic pathway of blood coagulation by activating factor IX. Defects in this factor lead to Rosenthal syndrome, a blood coagulation abnormality

Coagulation factor XI分子の別称

Coagulation factor XI,FXI,PTA,F11

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Asundexian	BAY-2433334	Phase 3 Clinical	Bayer AG	Atrial Fibrillation; Embolism; Hepatic Insufficiency; Ischemic Attack, Transient; Ischemic Stroke; Myocardial Infarction; Stroke; Thromboembolism	詳細
Cenvacibart	REGN7508	Phase 3 Clinical	Regeneron Pharmaceuticals Inc	Atrial Fibrillation; Peripheral Arterial Disease; Thrombosis; Venous Thromboembolism	詳細
Milvexian	BMS-986177; JNJ-70033093; JNJ-3093	Phase 3 Clinical	Bristol-Myers Squibb Company	Acute Coronary Syndrome; Atrial Fibrillation; Contraception; Coronary Thrombosis; Embolism; Ischemic Attack, Transient; Ischemic Stroke; Kidney Failure, Chronic; Renal Insufficiency; Stroke; Thromboembolism; Thrombosis	詳細
SHR-2004	SHR-2004	Phase 3 Clinical	Beijing Suncadia Medicine Co Ltd	Arterial Thromboembolism; Atrial Fibrillation; Dyslipidemias; Thromboembolism; Thrombosis; Venous Thromboembolism; Venous Thrombosis	詳細
Amrecibart	REGN-9933	Phase 3 Clinical	Regeneron Pharmaceuticals Inc	Atrial Fibrillation; Peripheral Arterial Disease; Venous Thromboembolism	詳細
Abelacimab	MAA-868; NOV-12	Phase 3 Clinical	Novartis Pharma Ag	Atrial Fibrillation; Embolism; Neoplasms; Pulmonary Embolism; Stroke; Thromboembolism; Venous Thromboembolism; Venous Thrombosis	詳細
EP-7041	EP-7041; HSK-36273	Phase 2 Clinical	Exithera Pharmaceuticals Inc	Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Thrombocytopenia; Thromboembolism; Thrombosis	詳細
Osocimab	BAY-1213790	Phase 2 Clinical	Bayer AG	Kidney Diseases; Kidney Failure, Chronic; Thromboembolism	詳細
IONIS-FXIRX	ISIS-404071; BAY-2306001; ISIS-FXIRX; FXI-ASO; IONIS-FXIRX; ISIS-416858	Phase 2 Clinical	Ionis Pharmaceuticals Inc	Thrombosis; Venous Thromboembolism	詳細
MK-2060	MK-2060	Phase 2 Clinical	Merck Sharp & Dohme Corp	Kidney Diseases; Kidney Failure, Chronic; Thromboembolism; Thrombosis	詳細
SRSD-107	SRSD-107; SRSD107	Phase 2 Clinical	Sirius Therapeutics Inc	Arterial Thromboembolism; Cardiovascular Diseases; Coronary Artery Disease; Coronary Disease; Peripheral Arterial Disease; Thromboembolism; Thrombosis; Venous Thromboembolism	詳細
RBD-4059	RBD-4059; RBD4059; SR059; SR-059	Phase 2 Clinical	Suzhou Ribo Life Science Co Ltd	Coronary Artery Disease; Coronary Disease; Kidney Failure, Chronic; Venous Thrombosis	詳細
KN-060	KN-060; KN060	Phase 2 Clinical	Suzhou Alphamab Co Ltd	Essential Hypertension; Hypertension; Kidney Failure, Chronic; Obesity; Overweight; Thromboembolism	詳細
Ir-CPI	BIOX-101; Ir-CPI	Phase 2 Clinical	Free University Of Brussels	Cerebral Hemorrhage	詳細
Fesomersen	ION-957943; IONIS-FXI-LRx; BAY-2976217	Phase 2 Clinical	Ionis Pharmaceuticals Inc	Nephrosis; Thromboembolism	詳細
ONO-7269	ONO-7269	Phase 1 Clinical	Ono Pharmaceutical Co Ltd	Cerebral Infarction	詳細
BAY-1831865	AB-012; BAY-1831865	Phase 1 Clinical	Aronora Inc	Thrombosis	詳細
A-336	A336; A-336	Phase 1 Clinical	Klus Pharma	Thromboembolism	詳細
A-186	A-186	Phase 1 Clinical	Sichuan Kelun Pharmaceutical Co Ltd	Thromboembolism	詳細
BMS-262084	BMS-262084	Phase 1 Clinical	Bristol-Myers Squibb Company	Thrombosis	詳細
ADX-626	ADX-626	Phase 1 Clinical	ADARx Pharmaceuticals Inc	Thrombosis	詳細
SBK-013	SBK013; SBK-013	Phase 1 Clinical	Chengdu Shibeikang Biomedical Technology Co Ltd	Arterial Thromboembolism; Thromboembolism; Venous Thromboembolism	詳細
XH-S002	XH-S002; XHS002	Phase 1 Clinical		Ischemic Attack, Transient; Stroke	詳細
BMS-986209	BMS-986209	Phase 1 Clinical	Bristol-Myers Squibb Company		詳細
NIP-003	NIP003; NIP-003; CRB4101; CRB-4101	Phase 1 Clinical	National Institutes Of Pharmaceutical Research And Development Co Ltd	Thromboembolism; Venous Thromboembolism; Venous Thrombosis	詳細
Factor XIa Inhibitor (Bayer)	Factor XIa Inhibitor (Bayer)	Phase 1 Clinical	Bayer AG	Blood Coagulation Disorders	詳細
SKB-336	SKB-336	Phase 1 Clinical	Sichuan Kelun-Biotech Biopharmaceutical Co Ltd	Embolism; Thromboembolism	詳細
SAL-0104	SAL-0104; SAL0104	Phase 1 Clinical	Suzhou Genemen Biotech Co Ltd	Cardiovascular Diseases; Embolism; Ischemic Attack, Transient; Myocardial Infarction; Stroke; Thrombosis; Venous Thromboembolism; Venous Thrombosis	詳細
STP122G	STP-122G; STP122G	Phase 1 Clinical	Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd	Embolism and Thrombosis	詳細
SHR2285	SHR-2285	Phase 1 Clinical	Jiangsu Hengrui Medicine Co Ltd	Embolism; Thromboembolism; Thrombosis; Venous Thromboembolism	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Factor XI concentrate (factor XI deficiency), CSL Behring		Approved	Csl Behring Llc		Australia	Factor XI Deficiency	Csl Behring Llc	2014-07-01	Factor XI Deficiency	詳細
Human coagulation Factor XI (LFB)		Approved	Lfb Biotechnologies Sas	Hemoleven	EU	Factor XI Deficiency	Lfb Biotechnologies Sas	1999-07-01	Factor XI Deficiency	詳細